|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 7/20/2016 9:51:14 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
EPA Regulations on Biotechnology
---Efficient Science-Based Review of Biotech Products
---EPA Points to Consider Guidance Document for GE Algae
---Reauthorization of Pesticide Registration Improvement Act (PRIA)
Food Waste
---H.R: 4184: The Food Recovery Act
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Like-minded Countries Initiatives
---Asynchronous Approvals
Funding for Biomass Crop Assistance Program
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Implementation of the Agricultural Act of 2014
Funding for the USDA
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to Restrict FDA Approval of GE Salmon
---Labeling
---S. 2634: The One Health Act
---H.R.505/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Review and Labeling of Food Derived from Biotechnology
---H.R. 1599: Safe and Accurate Food Labeling Act of 2015
---S. 764: Senate biotech labeling compromise bill
---S. 2609: The Biotech Labeling Solutions Act
Review of the Federal Coordinated Framework for Biotechnology Products
USDA/APHIS Agricultural Biotechnology Regulations
---Co-existence of Production Systems
---Efficient Science-Based Review of Biotech Products
---Potential Revisions to Part 340 Regulations
TransAtlantic Trade and Investment Partnership
---Ag-Biotech Issues
Potential Regulation of New Genetic Modification Technologies
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), White House Office, Office of Science & Technology Policy (OSTP), Environmental Protection Agency (EPA), Natl Security Council (NSC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Tom |
Dilenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Matthew |
OMara |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to Restrict FDA Approval of GE Salmon
---Labeling
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---S. 2634: The One Health Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Funding for Biofuels
---H.R.5293/S.3000: Department of Defense Appropriations Act for FY 2017
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for Biomass Crop Assistance Program
---H.R.5054-S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Implementation of the Agricultural Act of 2014
Funding for Centers for Disease Control and Prevention Vaccine Programs
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for FDA
---H.R. 5054 -S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for National Institutes of Health
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies
Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Funding for Renewable Chemicals/Bio-based Products
---H.R.5055/S.2804: Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Funding for the USDA
---H.R. 5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Energy Basic Research Funding
---H.R.5055/S.2804: Energy and Water Development and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phyllis |
Arthur |
|
|
|
Kelly |
Cappio |
|
|
|
Dan |
Durham |
|
|
|
Sarah |
Kyle |
|
|
|
Tracey |
LaTurner |
|
|
|
Erick |
Lutt |
|
|
|
Deborah |
Shelton |
|
|
|
Amy |
Walker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
EPA Regulations on Biotechnology
---Efficient Science-Based Review of Biotech Products
---Reauthorization of Pesticide Registration Improvement Act (PRIA)
---EPA Points to Consider Guidance Document for GE Algae
Funding for Renewable Chemicals/Bio-based Products
---H.R.5055 - S.2804: Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Renewable Chemicals/Bio-based Products (Non-Funding)
---Implementation of the Agricultural Act of 2014
---Investment Tax Credit for Renewable Chemicals and Bio-based Products
---New Production Tax Credit
---Nomenclature Usage
---Pre-market Notification Review
---Reauthorization of USDA Bio-Preferred Program
---H.R. 2576: TSCA Modernization Act
---H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
---S. 2271: The Renewable Chemical Production Tax Credit Act
---S. 696: The Safe Chemicals Act
---S. 697: Frank R. Lautenberg Chemical Safety for 21st Century Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Charles |
Fritts |
|
|
|
Tracey |
LaTurner |
|
|
|
Erick |
Lutt |
|
|
|
Dana |
OBrien |
|
|
|
Rina |
Singh |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---March-In Rights
Drug Patent Settlements
---S. 2019: Preserve Access to Affordable Generics Act of 2015
Intellectual Property International Enforcement
---Compulsory Licensing
---Colombia
---India
Inter Partes Review
---Implementation of the American Invents Act of 2011
---S.1137: The PATENTS Act of 2015
Patent Reform
---H.R. 9: Innovation Act
---S.1137: The PATENTS Act of 2015
TransPacific Partnership
---Data and Intellectual Property Protection for Pharmaceuticals
Transatlantic Trade and Investment Partnership
---Intellectual Property Issues
UN High-Level Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joseph |
Damond |
|
|
|
Tom |
Dilenge |
|
|
|
Charles |
Fritts |
|
|
|
Jamie |
Gregorian |
|
|
|
Sarah |
Kyle |
|
|
|
Nicolas |
Magallanes |
|
|
|
Matthew |
OMara |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Biosimilars
---Implementation of Affordable Care Act
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
---Biosimilar User Fee Act Reauthorization and Implementation
---Colombia Biologics Regulations
---Access to Samples for Testing
---S.3056: Creating and Restoring Equal Access to Equivalent Samples Act of 2016
Drug Importation
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies
Appropriations Act for FY 2017
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies
Appropriations Act for FY 2017
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to Restrict FDA Approval of GE Salmon
---Labeling
---S. 2634: The One Health Act
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Review and Labeling of Food Derived from Biotechnology
---H.R. 1599: Safe and Accurate Food Labeling Act of 2015
---S. 764: Senate biotech labeling compromise bill
---S.2609: The Biotech Labeling Solutions Act
USDA/APHIS Agricultural Biotechnology Regulations
---Co-existence of Production Systems
---Efficient Science-Based Review of Biotech Products
---Potential Revisions to Part 340 Regulations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Tom |
Dilenge |
|
|
|
Dan |
Durham |
|
|
|
Jamie |
Gregorian |
|
|
|
Kathleen |
Holcombe |
|
|
|
Tracey |
LaTurner |
|
|
|
Nicolas |
Magallanes |
|
|
|
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Implementation of the Agricultural Act of 2014
---Production Tax Credit Extension
---S. 2658: Federal Aviation Administration Reauthorization Act of 2016
----- Franken-Grassley Amendment
Energy Basic Research Funding
---DOE Office of Science
---H.R.5055/S.2804: Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Funding for Biofuels
---H.R.5293/S.3000: Department of Defense Appropriations Act for FY 2017
---H.R.5055/S.2804: Energy and Water Development and Related Agencies Appropriations for FY 2017
Funding for Biomass Crop Assistance Program
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Implementation of the Agricultural Act of 2014
Funding for Biorefineries
---Department of Defense Funding of Advanced Biofuels
Renewable Fuel Standard
---H.R.5538-S.3068: Departments of Interior, and Related Agencies Appropriations Act for FY 2017
---The 2014-2016 Final Rule
---EPA proposed rule for the Renewable Fuel Standard Program: Standards for 2017 and Biomass-Based Diesel Volume for 2018
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Dilenge |
|
|
|
Charles |
Fritts |
|
|
|
Tracey |
LaTurner |
|
|
|
Erick |
Lutt |
|
|
|
Dana |
OBrien |
|
|
|
Rina |
Singh |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Food Waste
---H.R. 4184: The Food Recovery Act
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to Restrict FDA Approval of GE Salmon
---Labeling
---S. 2634: The One Health Act
---H.R.505/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Review and Labeling of Food Derived from Biotechnology
---H.R. 1599: Safe and Accurate Food Labeling Act of 2015
---S. 764: Senate biotech labeling compromise bill
---S. 2609: The Biotech Labeling Solutions Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate only) |
|
|
|
Tom |
DiLenge |
|
|
|
Jamie |
Gregorian |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Implementation of the Agricultural Act of 2014
---Production Tax Credit Extension
---S. 2658: Federal Aviation Administration Reauthorization Act of 2016
----- Franken-Grassley Amendment
Energy Basic Research Funding
---DOE Office of Science
---H.R.5055/S.2804: Energy and Water Development and Related Agencies Appropriations Act for FY 2017
Funding for Biofuels
---H.R.5293/S.3000: Department of Defense Appropriations Act for FY 2017
---H.R.5055/S.2804: Energy and Water Development and Related Agencies Appropriations for FY 2017
Funding for Biomass Crop Assistance Program
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---Implementation of the Agricultural Act of 2014
Funding for Biorefineries
---Department of Defense Funding of Advanced Biofuels
Renewable Fuel Standard
---H.R.5538-S.3068: Departments of Interior, and Related Agencies Appropriations Act for FY 2017
---The 2014-2016 Final Rule
---EPA proposed rule for the Renewable Fuel Standard Program: Standards for 2017 and Biomass-Based Diesel Volume for 2018
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Charles |
Fritts |
|
|
|
Tracey |
LaTurner |
|
|
|
Erick |
Lutt |
|
|
|
Dana |
OBrien |
|
|
|
Rina |
Singh |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Drug Pricing Program
----Implementation of Affordable Care Act
---Program Implementation & Oversight
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Biodefense Research, Development and Procurement Issues (Nonfunding)
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act
Biosimilars
---Biosimilar User Fee Act Reauthorization and Implementation
---Colombia Biologics Regulations
---Implementation of Affordable Care Act
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
---Access to Samples for Testing
---S.3056: Creating and Restoring Equal Access to Equivalent Samples Act of 2016
Drug Evaluation and Review
---ADAPT Act (House Discussion Draft)
---Compassionate Use/Expanded Access
---FDA Proposed Rule on Changes to Drug Labeling
---Implementation of the FDA Safety and Innovation Act
---Reauthorization of the Prescription Drug User Fee Act
Drug Importation
---H.R.5054 - S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R.5325-S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Funding for Centers for Disease Control and Prevention Vaccine Programs
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Funding for FDA
---H.R. 5054 -S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
Funding for National Institutes of Health
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Medicaid Pricing and Rebates
---Average Manufacturer Price Calculations
---Implementation of Affordable Care Act
Orphan Drug Act Tax Credit
Precision Medicine Initiative
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
-- --CMMI Medicare Part B Proposed Demonstration Project
---Medicare Part D Prescription Drug Program
---Value-based Contracting and Communications
Senate Innovation for Healthier Americans
---Biomarkers and Regulatory Science Improvements
---Communication with Healthcare Professionals and Payors
---Expanded Access to Investigational Drugs
---Expedited Pathways
---FDA Hiring Flexibility
---Innovation Incentives
---Longitudinal Study of Chronic Diseases
---Patient Access to Approved Drugs
---Patient-Focused Drug Development
---Priority Review Voucher Programs
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---- S. 195: PATH Act
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act
---H.R. 4762: Reliable and Effective Growth for Regenerative Health Options that Improve Wellness (REGROW) Act
---S. 1878: Advancing Hope Act of 2015
---S. 2912: Trickett Wendler Right to Try Act of 2016
---S.2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act
---S.524: Comprehensive Addiction and Recovery Act of 2016
---The KIDS Act
UN High Level Commission on Access to Medicines
Vaccine Access/Financing
---Adult Immunization (Senate Discussion Draft)
---Senate Chronic Care Working Group Proposals
---Vaccine Injury Compensation Program
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Vaccines and Infectious Diseases - General
---H.R. 3299: Strengthening Public Health Emergency Response Act
---S.2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
Drug Manufacturing, Quality & Distribution
---Pharmacy Compounding & Oversight
---Vial and Dose Size
Gene Editing Technologies
---S.3040-H.R.5325: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Generic Drug Entry
---S. 2615: Increasing Competition in Pharmaceuticals Act
---S.3056: Creating and Restoring Equal Access to Equivalent Samples Act of 2016
Government Price Reporting
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Antibiotic & Diagnostic Tax Credit
---H.R. 3539: Antibiotic & Diagnostic Innovation Act
TransPacific Partnership
---Data and Intellectual Property Protection for Pharmaceuticals
Transatlantic Trade and Investment Partnership
---Intellectual Property Issues
---Regulatory Harmonization
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phyllis |
Arthur |
|
|
|
Kelly |
Cappio |
|
|
|
Charles |
Crain |
|
|
|
Joseph |
Damond |
|
|
|
Dan |
Durham |
|
|
|
Tom |
DiLenge |
|
|
|
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Jamie |
Gregorian |
|
|
|
Erin |
Hertzog |
|
|
|
Kathleen |
Holcombe |
|
|
|
Sarah |
Kyle |
|
|
|
Tracey |
LaTurner |
|
|
|
Nicolas |
Magallanes |
|
|
|
Scott |
McGoohan |
|
|
|
Matthew |
OMara |
|
|
|
Deborah |
Shelton |
|
|
|
Laurel |
Todd |
|
|
|
Amy |
Walker |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Nonfunding)
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phyllis |
Arthur |
|
|
|
Kelly |
Cappio |
|
|
|
Dan |
Durham |
|
|
|
Sarah |
Kyle |
|
|
|
Tracey |
LaTurner |
|
|
|
Nicolas |
Magallanes |
|
|
|
Amy |
Walker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Nonfunding)
---S. 2055/H.R. 3299: Medical Countermeasures Innovation Act
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Funding for National Institutes of Health
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
---Supplemental Funding for Combating Zika
---H.R. 2577: The Zika Response Appropriations Act of 2016
Gene Editing Technologies
---S.3040-H.R.5325: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Precision Medicine Initiative
Senate Innovation for Healthier Americans
---Longitudinal Study of Chronic Diseases
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phyllis |
Arthur |
|
|
|
Kelly |
Cappio |
|
|
|
Dan |
Durham |
|
|
|
Cartier |
Esham |
|
|
|
Kathleen |
Holcombe |
|
|
|
Sarah |
Kyle |
|
|
|
Tracey |
LaTurner |
|
|
|
Nicolas |
Magallanes |
|
|
|
Amy |
Walker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Government Price Reporting
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Medicaid Pricing and Rebates
---Average Manufacturer Price Calculations
---Implementation of Affordable Care Act
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
-- --CMMI Medicare Part B Proposed Demonstration Project
---Medicare Part D Prescription Drug Program
---Value-based Contracting and Communications
Senate Innovation for Healthier Americans
---Patient Access to Approved Drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Dan |
Durham |
|
|
|
Jamie |
Gregorian |
|
|
|
Erin |
Hertzog |
|
|
|
Tracey |
LaTurner |
|
|
|
Nicolas |
Magallanes |
|
|
|
Laurel |
Todd |
|
|
|
Jeanne |
Haggerty |
|
|
|
Deborah |
Shelton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Synthetic Biology Issue
---H.R. 591: Engineering Biology Research and Development Act
Review of the Federal Coordinated Framework for Biotechnology Products
Gene Editing Technologies
---S.3040-H.R.5325: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Kathleen |
Holcombe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Dana |
OBrien |
|
|
|
Brian |
Baenig (House and Senate Only) |
|
|
|
Matthew |
O'Mara |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Formation Investment Incentives
---H.R. 2179: PARTNER Act
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
---S. 341: Start-up Jobs and Innovation Act
---S. 537: COMPETE Act
Capital Market Enhancements
---H.R. 1675/S. 576: Encouraging Employee Ownership Act
---H.R. 1675: Capital Markets Improvement Act
---H.R. 2354: Streamlining Excessive and Costly Regulations Review Act
---H.R. 2357: Accelerating Access to Capital Act
---H.R. 3784/S.2867: Securities & Exchange Commission Small Business Advocate Act
---H.R. 4168: Small Business Capital Formation Enhancement Act
---H.R. 4638: Main Street Growth Act
---H.R. 2187: Fair Investment Opportunities for Professional Experts Act
---Financial CHOICE Act (House Discussion Draft)
Small Business Innovation Research (SBIR) Program
Proxy Advisory Services
---Impact of Policies on Small Public Companies
---H.R. 5311: The Corporate Governance Reform and Transparency Act of 2016
---Financial CHOICE Act (House Discussion Draft)
Reform of SEC Regulation D
---H.R. 4498/S.978: HALOS Act
---H.R. 4852: Private Placement Improvement Act
---Financial CHOICE Act (House Discussion Draft)
Sarbanes Oxley Section 404 (b)
---H.R. 4139: Fostering Innovation Act
---PCAOB Audit Cost Increases
---Small Issuer Exemption
---Financial CHOICE Act (House Discussion Draft)
Short Selling Transparency
---H.R.5485/S.3067: Financial Services and General Government Appropriations for FY 2017
XBRL Exemption for Small Public Companies
---H.R. 1675: Capital Markets Improvement Act
---H.R. 1965: Small Company Disclosure Simplification Act
---Financial CHOICE Act (House Discussion Draft)
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Tom |
Dilenge |
|
|
|
Charles |
Fritts |
|
|
|
Sarah |
Kyle |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Antibiotic & Diagnostic Tax Credit
---H.R. 3539: Antibiotic & Diagnostic Innovation Act
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Production Tax Credit Extension
Capital Formation Investment Incentives
---H.R. 2179: PARTNER Act
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
---S. 341: Start-up Jobs and Innovation Act
---S. 537: COMPETE Act
Inversions
---H.R.5485-S.3067: Financial Services and General Government Appropriations Act for FY 2017
Orphan Drug Act Tax Credit
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R. 3390: Qualifying Renewable Chemicals Production or Investment Tax Credit Act
---Investment Tax Credit for Renewable Chemicals and Bio-based Products
---New Production Tax Credit
---S. 2271: The Renewable Chemical Production Tax Credit Act
Research & Development Tax Credit Reforms
---Refundable R&D Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Tracey |
LaTurner |
|
|
|
Erick |
Lutt |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Rina |
Singh |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
TransPacific Partnership
---Data and Intellectual Property Protection for Pharmaceuticals
Transatlantic Trade and Investment Partnership
---Intellectual Property Issues
---Regulatory Harmonization
---Ag-Biotech Issues
Biosimilars
---Colombia Biologics Regulations
---Mexico Biologics Regulations
Drug Importation
---H.R.5054/S.2956: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2017
---H.R.5325/S.3040: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2017
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Like-minded Countries Initiatives
---Asynchronous Approvals
Intellectual Property International Enforcement
---Compulsory Licensing
---Colombia
---India
UN High Level Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Natl Security Council (NSC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joseph |
Damond |
|
|
|
Tom |
DiLenge |
|
|
|
Charles |
Fritts |
|
|
|
Kathleen |
Holcombe |
|
|
|
Tracey |
LaTurner |
|
|
|
Nicolas |
Magallanes |
|
|
|
Matthew |
OMara |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |